Crossmark

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia

Published Online: 2015-08-12

Published Print: 2016-01

Authors

Akahane, K

Sanda, T https://orcid.org/0000-0003-1621-4954
Mansour, M R

Radimerski, T

DeAngelo, D J

Weinstock, D M

Look, A T
License Information

Text and Data Mining valid from 2015-08-12

Version of Record valid from 2015-08-12
More Information

Article History

Received: 27 March 2015

Revised: 1 July 2015

Accepted: 4 August 2015

First Online: 12 August 2015

Competing interests

: Dr Radimerski is an employee of Novartis. Dr Weinstock receives research funding and is a consultant for Novartis. The remaining authors declare no conflict of interest.

Document is current